IMUX Immunic
- 1.130
- 0.0000.00%
- 1.150
- +0.020+1.77%
Immunic News
Immunic | 8-K: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic | 8-K: Immunic hosts multiple sclerosis research and development day
Immunic | 8-K: Addendum No. Six to Employment Agreement
Immunic | 8-K: Immunic Appoints Simona Skerjanec to Board of Directors
Immunic | 8-K: Immunic Appoints Jason Tardio as Chief Operating Officer and President
Immunic | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Immunic | 8-K: Poll Results of 2024 Stockholders Meeting
Immunic | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
Immunic | DEF 14A: Definitive information statements
Immunic | 8-K: Poll Results of Special Meeting
Immunic | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
Immunic | 8-K: Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Immunic | S-3: Registration statement for specified transactions by certain issuers
Immunic | DEF 14A: Definitive information statements
Immunic | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Immunic | 8-K: Entry into Securities Purchase Agreement and Highlights 2023 Accomplishments and Upcoming Milestones
Immunic | 8-K: Immunic Amends Service Agreements for Various Members of the Management Team of Wholly-Owned Subsidiary Immunic AG
Immunic | S-3: Registration statement for specified transactions by certain issuers
Immunic | 8-K: Entry into a Material Definitive Agreement
Immunic | 8-K: Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
No Data